Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

176 Press Releases
DateTitleCompany
09 Aug 12 Takeda and Affymax Announce Supply Agreement for OMONTYS® (peginesatide) Injection with U.S. Renal Care, Inc. Takeda Pharmaceuticals U.S.A.,
Published by
Business Wire
27 Jul 12 Sucampo and Takeda Announce Filing of Supplemental New Drug Application for AMITIZA (Lubiprostone) in Opioid-induced Constipation Sucampo Pharmaceuticals Inc. and Takeda,
Published by
Business Wire
20 Jul 12 Millennium and Takeda Announce Positive CHMP Opinion for Conditional Approval of ADCETRIS® (brentuximab vedotin) in Europe Millennium: The Takeda Oncology Company,
Published by
Business Wire
20 Jul 12 Takeda and Millennium Announce Positive CHMP Opinion for Conditional Approval of ADCETRIS® (brentuximab vedotin) in Europe Takeda Pharmaceutical Company Limited,
Published by
Business Wire
12 Jul 12 Takeda and Affymax Announce Supply Agreement for OMONTYS® (peginesatide) Injection with Fresenius Medical Care North America Takeda Pharmaceuticals U.S.A. and Affymax Inc.,
Published by
Business Wire
28 Jun 12 Millennium Initiates TOURMALINE-MM1 Pivotal Phase 3 Trial of MLN9708 in Patients With Relapsed and/or Refractory Multiple Myeloma Millennium: The Takeda Oncology Company,
Published by
Business Wire
14 Jun 12 Millennium Highlights Updated Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Trial in Patients with Relapsed or Refractory Hodgkin Lymphoma Millennium: The Takeda Oncology Company,
Published by
Business Wire
03 Jun 12 ASCO Presentations Highlight Preliminary Results of Studies with MLN9708, First Oral Proteasome Inhibitor in Clinical Trials in Multiple Myeloma Millennium: The Takeda Oncology Company,
Published by
Business Wire
25 May 12 Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil Takeda Pharmaceutical Company Limited
23 May 12 Millennium and Takeda Announce Presentations for Key Investigational Molecules at American Society of Clinical Oncology Annual Meeting Millennium: The Takeda Oncology Company,
Published by
Business Wire
07 May 12 Millennium and Seattle Genetics Initiate Global Phase 3 Trial of ADCETRIS™ in Patients with CD30-Expressing Relapsed Cutaneous T-cell Lymphoma Millennium: The Takeda Oncology Company and Seattle Genetics Inc.,
Published by
Business Wire
11 Apr 12 Takeda to Acquire URL Pharma Takeda Pharmaceutical Company Limited (Takeda),
Published by
F T I Consulting
06 Apr 12 Presage Biosciences and Millennium Enter Into Cancer Research Agreement Millennium: The Takeda Oncology Company,
Published by
Business Wire
20 Feb 12 Takeda Announces Primary Endpoints Met for Pivotal Phase 3 Trial of Vedolizumab in Patients with Moderately to Severely Active Ulcerative Colitis Who Have Failed at Least One Conventional Therapy Takeda Pharmaceutical Company Limited,
Published by
Business Wire
24 Jan 12 FDA Approves Subcutaneous Administration of VELCADE® In All Approved Indications Millennium: The Takeda Oncology Company,
Published by
Business Wire
20 Jan 12 Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth Takeda Pharmaceutical Company Limited
22 Dec 11 Takeda snaps up Intellikine to boost cancer pipeline Takeda
21 Dec 11 Takeda to Acquire Intellikine, Adding Two Novel Programs to its Oncology Pipeline Millennium: The Takeda Oncology Company,
Published by
Business Wire
20 Dec 11 Presentations Highlight Results of Clinical Data for MLN8237 and VELCADE® in the Treatment of Lymphoma Millennium: The Takeda Oncology Company,
Published by
Business Wire
13 Dec 11 Presentations Highlight Results of Studies with MLN9708, First Oral Proteasome Inhibitor in Early Stage Clinical Trials in Multiple Myeloma Millennium: The Takeda Oncology Company,
Published by
Business Wire
13 Dec 11 Overall Survival Benefit with VELCADE® Based Therapy in Previously Untreated Multiple Myeloma Patients Maintained After Five Year Follow-Up Millennium: The Takeda Oncology Company,
Published by
Business Wire
22 Nov 11 Takeda Appoints Jostein Davidsen Head of Emerging Markets Takeda
08 Nov 11 More than Thirty Abstracts on VELCADE® and Leading Millennium Pipeline Compounds to be Presented in Oral Sessions at 53rd American Society of Hematology Annual Meeting Millennium: The Takeda Oncology Company,
Published by
Business Wire
02 Nov 11 FDA Approves Addition of Sustained Overall Survival Advantage (5-year follow-up) to Label for VELCADE® in Patients with Previously Untreated Multiple Myeloma Millennium: The Takeda Oncology Company,
Published by
Business Wire
06 Oct 11 Millennium Provides Update on sNDA for VELCADE in Relapsed Follicular Lymphoma Millennium: The Takeda Oncology Company,
Published by
Business Wire
24 Sep 11 Millennium and Seattle Genetics Present Clinical Data on ADCETRIS™ (Brentuximab Vedotin) in Pediatric Patients at EMCC Annual Meeting Millennium: The Takeda Oncology Company and Seattle Genetics Inc.,
Published by
Business Wire
16 Sep 11 Millennium Ranked In Top 10 Biotech / Biopharmaceutical Companies For 4th Consecutive Year Millennium: The Takeda Oncology Company,
Published by
Business Wire
19 Jul 11 Millennium Submits Supplemental New Drug Application with FDA for Long-Term Overall Survival Results of VELCADE in Previously Untreated Multiple Myeloma Millennium: The Takeda Oncology Company,
Published by
Business Wire
27 Jun 11 Millennium Announces EMA Acceptance of Marketing Authorization Application for ADCETRIS™ (Brentuximab Vedotin) Millennium: The Takeda Oncology Company,
Published by
Business Wire
23 Jun 11 Data on MLN8237, an Investigational Aurora A Kinase Inhibitor, Presented at International Lymphoma Conference Millennium: The Takeda Oncology Company,
Published by
Business Wire
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.